Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 11/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | PDE6D | O43924 | 1/20 | 0.39 |
| ▸ | PDE6A | P16499 | 1/20 | 0.39 |
| ▸ | PDE6G | P18545 | 1/20 | 0.39 |
| ▸ | PDE6B | P35913 | 1/20 | 0.39 |
| ▸ | PDE6C | P51160 | 1/20 | 0.39 |
| ▸ | PDE6H | Q13956 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5371025 | 0.95 | PDE5A (0.41) | PDE5AMAPT | |
| SCHEMBL6709453 | 0.83 | MAPT (0.45) | PDE5AMAPT | |
| SCHEMBL5361166 | 0.82 | PDE5A (0.41) | PDE5AMAPT | |
| SCHEMBL4762020 | 0.82 | PDE5A (0.47) | PDE5A | |
| SCHEMBL4762165 | 0.82 | PDE5A (0.44) | PDE5AMAPT | |
| SCHEMBL4762021 | 0.81 | PDE5A (0.40) | PDE5A | |
| SCHEMBL29380456 | 0.80 | MAPT (0.44) | PDE5AMAPT | |
| SCHEMBL3142074 | 0.80 | MAPT (0.44) | PDE5AMAPT | |
| SCHEMBL4762032 | 0.80 | SMN1; SMN2 (0.41) | PDE5A | |
| SCHEMBL5248552 | 0.80 | MAPT (0.44) | PDE5AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1432715-B1 | PYRIMIDINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2008-03-19 | — | — | EP | claimed |
| US-7312224-B2 | Pyrimidine derivatives | MERCK PATENT GMBH (DE) | 2007-12-25 | — | — | US | claimed |
| US-20040242595-A1 | Pyrimidine derivatives | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2004-12-02 | — | — | US | claimed |
| US-7312224-B2 | Pyrimidine derivatives | MERCK PATENT GMBH (DE) | 2007-12-25 | — | — | US | disclosed |
| US-20040242595-A1 | Pyrimidine derivatives | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2004-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040242595-A1 | Pyrimidine derivatives | TYMP, DPYD, TYMS | PDE5A 16/4885MAPT 4707/4885PDE6D 99/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.